Tuesday, February 17, 2026 2/17/2026

Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application

Award Number: SB1EY027241
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2016
PERIOD OF PERFORMANCE END DATE: 12/31/2019

Group Awards By:

View Award Description

Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application - Abstract In this Commercialization Readiness Pilot (CRP) Program application, we propose to commercialize and bring to market EyeArt, a fully automated, high throughput, retinal image analysis based diabetic retinopathy (DR) screening tool (which has been developed and already validated in bench tests on very large real-world data) by developing and executing a market access plan, conducting a pilot clinical study, and formulating an intellectual property strategy. With its fully-automated use, real-world applicability (handles variable number of images per patient including poor quality and external eye images), high throughput capability (can analyze thousands of patient cases in just a few hours), scalable cloud-based architecture, and ability to seamlessly integrate into clinical workflows, EyeArt will aid the expansion of DR screening and help bridge the fast growing disparity between the number of diabetic patients and the number of eye care providers. DR is a common microvascular complication of diabetes potentially affecting 80% of all diabetic patients. Even though vision loss due to DR is preventable by early detection and treatment, DR remains to be one of the leading global causes of preventable blindness primarily due to the lack of easy access to eye care providers. Automated DR screening is the only way to make DR screening more accessible to the large and growing population of diabetic patients, currently 29 million in the US, 387 million world-wide and expected to grow to 110 million and 592 million respectively by 2030. To help reduce risk of DR related vision loss in the diabetic population, EyeArt uses advanced image analysis algorithms to make DR screening more efficient, cost-effective, and accessible. EyeArt has been validated and shown to have high screening safety (sensitivity) and efficacy (specificity) on multiple large real- world datasets including one with over 30,000 patient cases (and 240,000 images). Eyenuk has received ISO 13485 certification as a medical device manufacturer and EyeArt has received CE Marking and is commercially available in Europe. We will clinically validate EyeArt in formal clinical trials which will pave the way for EyeArt’s availability in the US DR screening market. EyeArt will reduce the burden on clinical resources by improving health care productivity, and also help increase the DR screening conformance in the diabetic population and thus aid in reducing and ultimately eliminating vision loss due to DR through early detection and treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	EYENUK, INC.	5850 CANOGA AVE STE 250	WOODLAND HILLS	CA	91367	LOS ANGELES	USA	Vision Research	000	8	6/26/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $499,050 )
2018	2018	EYENUK, INC.	5850 CANOGA AVE STE 250	WOODLAND HILLS	CA	91367	LOS ANGELES	USA	Vision Research	000	8	8/3/2018	NON-COMPETING CONTINUATION	$499,050
														Subtotal = $499,050

Issue Date FY: 2017 ( Subtotal = $499,531 )
2017	2017	EYENUK, INC.	21860 BURBANK BLVD STE 160	WOODLAND HILLS	CA	91367	LOS ANGELES	USA	Vision Research	000	7	9/1/2017	NON-COMPETING CONTINUATION	$499,531
														Subtotal = $499,531

Issue Date FY: 2016 ( Subtotal = $500,000 )
2016	2016	EYENUK INC	22130 CLARENDON STREET	SAN LUIS OBISPO	CA	91367		USA	Vision Research	000	6	9/26/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$500,000
														Subtotal = $500,000

Grand Total All Awards = $1,498,581

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application

Award Number: SB1EY027241

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2016

PERIOD OF PERFORMANCE END DATE: 12/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer